'Generic Drugs Market Will Reach $127.8 Billion in 2013' Predicts new Visiongain Report

Informations

• Publié par: visiongain
• Nombre de lectures: 17
• Langue: English

Extrait

'Generic Drugs Market Will Reach $127.8 Billion in 2013' Predicts new Visiongain Report

PR Newswire LONDON, November 28, 2012

LONDON,November 28, 2012/PRNewswire/ --

A new report byvisiongainpredicts that the world market for genericpharmaceuticalswill reach$127.8bnin 2013. That revenue forecast and others appear inGeneric Drugs: World Market 2013-2023, published inNovember 2012. Visiongain is a business information provider based in London, UK.

The world prescription generic drug industry stands at$110.8bnin 2011. If a more general definition of off-patent medicines is used to define generics, some estimates put the size of the industry at over$150bn. In the US, generic drug sales have more than tripled since 2000. Sales of generics there currently represent over 40% of worldwide sales, with generic drugs accounting for about 70% of the prescriptions dispensed in the US. This percentage is likely to increase as novel branded drugs face further competition from generic products. Other countries will experience similar trends, the report finds.

Visiongain forecasts that the overall generic drugs market will grow steadily to 2023. As general life expectancy rises, increasing numbers of elderly people in developed countries - and growing numbers of middle class consumers in developing countries - raise the demand for affordable medicines, especially generic drugs. There are many opportunities for companies providing generics, though competition is high in many national and therapeutic markets.

Dr Syed Ahmed, a senior pharmaceutical industry analyst in visiongain, said: "A number of factors have contributed to the growth of the world generics market. Prominent blockbuster drugs will lose patent protection in the next few years, with many having done so already. Novel pharmaceutical manufacturers are set to lose over$50bnin sales due to patent expiry in 2013 alone. That situation presents great opportunities for generics producers over the next 10 years. Also, growth in the generics industry and market will continue steadily as legislative demands to control healthcare costs increase, especially in the US and European markets. Many healthcare payers demand generic substitutes for branded prescription medicines, especially drugs with wide use.

"In addition, other growth drivers for the generics industry and market include a trend for innovator pharmaceutical companies to establish a presence in the generics m arket. To overcome what is perceived as big pharma's continued innovation drought, leading companies such as Pfizer, Novartis and Sanofi have built partnerships with generic drug producers or purchased generic drug operations. Generics manufacturing companies seeking to increase scale, revenue, market share and competitive advantages have also been involved in mergers and acquisitions. Leading generics companies have also been active in geographical expansion, especially into developing countries. We predict those trends will continue."

Visiongain's report shows revenue forecasts to 2023 at overall world market and national level. Research, data and analyses cover activities of Teva, Sandoz (Novartis), Mylan, Apotex, Hospira, Watson and other generics specialists, as well as other pharma companies.

That study discusses developments and commercial news, shows research interviews and predicts individual revenues to 2023 in leading national markets. The w ork analyses the US, Japan, the UK, Germany, France , Spain, Italy, Turkey, Brazil, Mexico, South Korea, the Russian Federation, India and China.

Generic Drugs: World Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the Visiongain report Generic Drugs: World Market 2013- 2023, please visit: http://www.visiongain.com/Report/932/Generic-Drugs-World-Market-2013-2023

For an executive summary please contact: Email: Sara Peerun [e-mail] Tel: [phone]

Companies Listed Abbott Laboratories

Aché Laboratórios Farmacêuticos Actavis Altra Investments Amgen Andrx Andrx Corporation Apotex APP Pharmaceuticals Arrow Group Ascent Pharmahealth Asociación Española de Fabricantes de Sustancias y Especialidades Farmacéuticas Genéricas (AESEG) Aspen Assogenerici - Associazione Nazionale Industrie Farmaci Generici AstraZeneca Aurobindo Pharma Barr Pharmaceuticals Bayer HealthCare Bedford Laboratories Beijing MedPharm Bioniche Pharma Holdings Biopartners Biotechnology Industry Organization (BIO) Blue Cross Blue Shield Association (BCBSA) BMP Sunstone Boehringer Ingelheim Bristol-Myers Squibb British Generics Manufacturers Association (BGMA) Cangene Corporation Celltrion Centers for Medicare and Medicaid Services Cephalon Chon Kun Dang Cipla Claris Lifesciences CoGenesys Committee for Medicinal Products for Human Use (CHM P) Congressional Budget Office (CBO) Corporación Infarmasa ("Infarmasa", Peru) Corporación Infarmasa [Peru] Daiichi Sankyo Dey Pharma DOC Generici Dr. Reddy's Laboratories Ebewe Pharma Eden Biodesign Egis Eisai Pharmaceuticals Eli Lilly EMS Sigma Pharma Eon Labs Eurofarma Laboratorios European Commission (EC) European Court of Justice European Generic Medicines Association (EGA) European Medicines Agency (EMA/EMEA) European Union (EU) Famy Care Farmacia del Ahorro Farmacias Similares Federal Trade Commission (FTC) Finox Food and Drug Administration (US FDA) Fuji Pharma Gedeon Richter Genentech Generic Pharmaceutical Association (GPhA) German Association of Pharmacists (ABDA) GlaxoSmithKline (GSK) Glenmark Pharmaceuticals Greenstone (Pfizer) H. Lundbeck Health, Education, Labor and Pensions (HELP, US Senate Committee) Healthcare Economics LLC Hexal

Hospira Hospira Healthcare India Intas Biopharmaceuticals IVAX Javelin Pharmaceuticals Johnson & Johnson Jubilant Organosys Kowa Pharmaceuticals Krka Laboratorios Best Laboratorios Kendrick Lareq Pharma Lek Pharmaceuticals Lundbeck Lupin Pharmaceuticals MasterLek Matrix Matrix Laboratories Mayne Pharma Medi-Mart Medley Pharmaceuticals Merck & Co. Merck KGaA Ministry of Health, Labour and Welfare [Japan] Mundipharma International Mylan Institutional Mylan Laboratories Mylan Pharmaceuticals Mylan Seiyaku National Health Service (UK NHS) National Institute for Biological Standards and Control (NIBSC, UK) Nichi-iko Pharmaceutical Nippon Chemiphar Novartis NOVN.V Hexal Office of Generic Drugs (OGD, US FDA) Onco Therapies Orchid Chemicals & Pharmaceuticals Oriel Therapeutics Parexel Consulting Pfizer Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmstandard Piramal Healthcare Pliva Purdue Pharma Ranbaxy Laboratories Ratiopharm RBC Capital Markets Roche Samsung Sanborns Sandoz Sanofi (formerly sanofi-aventis) Sawai Pharmaceuticals Shire Pharmaceuticals SICOR Sigma Pharmaceuticals SK Chemicals Specifar Pharmaceuticals SA Stada Arzneimittel AG Strides Arcolab Sun Pharmaceuticals Taisho Pharmaceutical Industries Taiyo Pharmaceuticals Takeda Pharmaceutical Company Tecnofarma Teva Parenteral Medicines Teva Pharmaceutical Industries The Rohatyn Group Theramex Topgen Towa Pharmaceutical UCB

UDL Laboratories UK Department of Health Veropharm Vinca Wal-Mart Warner Chilcott Watson Laboratories Watson Pharmaceuticals Wockhardt World Trade Organization (WTO) Wyeth Zentiva Zydus Cadila

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to [e-mail] call her on [phone]

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies inEurope. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.